Evolus filed three material events with the SEC (March 13, May 4, and June 12, 2026), suggesting material business developments for the Jeuveau (botulinum toxin type A) franchise. Evolus has built its market strategy on aggressive pricing and rebate programs targeting independent medspas and smaller practices — the customer base most price-sensitive to Allergan's Botox dominance.
Business & M&A
Evolus Files Multiple Material Events — Jeuveau Competitive Pricing Strategy in Motion
Evolus has filed three SEC 8-Ks; the company is likely adjusting Jeuveau pricing or Evolus Rewards rebate terms to capture market share from Allergan.
